Top

08-04-2024 | Imatinib | Original Article

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

Authors: Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, Tomonori Nakazato, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Yoshihiro Hatta, Tatsuya Kawaguchi

Published in: International Journal of Hematology

Abstract

This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall survival, and CML-related death (CRD) did not differ significantly between groups. When stratified by risk scores, the prognostic performance of the ELTS score was superior to that of the Sokal score. Even though both scoring systems predicted CRD in the imatinib era, only the ELTS score predicted CRD in the 2G-TKI era. Notably, the outcome of patients classified as high-risk by ELTS score was more favorable in the 2G-TKI era group than in the imatinib era group. Thus, expanding treatment options may have improved patient outcomes in CP-CML, particularly in patients classified as high-risk by ELTS score.

Available only for authorised users

Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72. https://doi.org/10.1056/NEJM199907153410306.CrossRefPubMed

Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914–26. https://doi.org/10.1016/S0140-6736(21)01204-6.CrossRefPubMed

Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. 2016;101(6):657–9. https://doi.org/10.3324/haematol.2016.142877.CrossRefPubMedPubMedCentral

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. https://doi.org/10.1056/NEJMoa1609324.CrossRefPubMedPubMedCentral

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. https://doi.org/10.1038/s41375-020-0776-2.CrossRefPubMedPubMedCentral

Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(10):1385–415. https://doi.org/10.6004/jnccn.2020.0047.CrossRefPubMed

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019;109(4):426–39. https://doi.org/10.1007/s12185-019-02613-1.CrossRefPubMed

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. https://doi.org/10.1200/JCO.2015.64.8899.CrossRefPubMedPubMedCentral

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–53. https://doi.org/10.1038/s41375-020-01111-2.CrossRefPubMedPubMedCentral

10.

Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825–33. https://doi.org/10.1038/s41375-022-01589-y.CrossRefPubMedPubMedCentral

11.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. https://doi.org/10.1182/blood-2013-05-501569.CrossRefPubMedPubMedCentral

12.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244.CrossRef

13.

Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35(5):585–90. https://doi.org/10.1016/j.leukres.2010.10.027.CrossRefPubMed

14.

Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103(6):1071–8. https://doi.org/10.1111/j.1349-7006.2012.02253.x.CrossRefPubMedPubMedCentral

15.

Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022;115(1):33–42. https://doi.org/10.1007/s12185-021-03216-5.CrossRefPubMed

16.

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105(6):792–804. https://doi.org/10.1007/s12185-017-2208-2.CrossRefPubMed

17.

Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528-35. https://doi.org/10.1016/S2352-3026(15)00196-9.CrossRefPubMed

18.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185–93. https://doi.org/10.1007/s12185-017-2334-x.CrossRefPubMed

19.

Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835–42. https://doi.org/10.3324/haematol.2018.194894.CrossRefPubMedPubMedCentral

20.

Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182–92. https://doi.org/10.1111/cas.13430.CrossRefPubMed

21.

Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, et al. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020;111(3):401–8. https://doi.org/10.1007/s12185-019-02801-z.CrossRefPubMed

22.

Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):e218-25. https://doi.org/10.1016/S2352-3026(19)30235-2.CrossRefPubMed

23.

Narlı Özdemir Z, Kılıçaslan NA, Yılmaz M, Eşkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023;117(1):3–15. https://doi.org/10.1007/s12185-022-03446-1.CrossRefPubMed

24.

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56. https://doi.org/10.1038/leu.2015.261.CrossRefPubMed

25.

Molica M, Canichella M, Alunni Fegatelli D, Colafigli G, Massaro F, Latagliata R, et al. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. Am J Hematol. 2017;92(12):E661-4. https://doi.org/10.1002/ajh.24913.CrossRefPubMed

26.

Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia. 2018;32(10):2299–303. https://doi.org/10.1038/s41375-018-0136-7.CrossRefPubMed

27.

Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138–49. https://doi.org/10.1038/s41375-020-0931-9.CrossRefPubMedPubMedCentral

28.

Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, et al. Prognostic factors for overall survival in chronic myeloid leukemia patients: a multicentric cohort study by the Italian CML GIMEMA Network. Front Oncol. 2021;11: 739171. https://doi.org/10.3389/fonc.2021.739171.CrossRefPubMedPubMedCentral

29.

Szczepanek E, Chukwu O, Kamińska M, Wysogląd H, Cenda A, Zawada M, et al. Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience. Leuk Lymphoma. 2022;63(9):2213–23. https://doi.org/10.1080/10428194.2022.2068000.CrossRefPubMed

30.

Yang X, Bai Y, Shi M, Zhang W, Niu J, Wu C, et al. Validation of the EUTOS long-term survival score in Chinese chronic myeloid leukemia patients treated with imatinib: a Multicenter Real-World Study. Cancer Manag Res. 2020;12:1293–301. https://doi.org/10.2147/CMAR.S237467.CrossRefPubMedPubMedCentral

31.

Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022;36(2):482–91. https://doi.org/10.1038/s41375-021-01387-y.CrossRefPubMed

32.

Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020;9(23):8931–9. https://doi.org/10.1002/cam4.3516.CrossRefPubMedPubMedCentral

33.

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. https://doi.org/10.1183/13993003.00879-2022.CrossRefPubMed

34.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–71. https://doi.org/10.1038/leu.2016.104.CrossRefPubMedPubMedCentral

35.

Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018;97(11):2081–8. https://doi.org/10.1007/s00277-018-3412-8.CrossRefPubMed

36.

Iriyama N, Tokuhira M, Sato E, Sugimoto KJ, Takaku T, Ishikawa M, et al. Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: a retrospective analysis. Hematol Oncol. 2019;37(3):323–5. https://doi.org/10.1002/hon.2617.CrossRefPubMed

Title: Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
Authors: Noriyoshi Iriyama
Eisaku Iwanaga
Yuta Kimura
Naoki Watanabe
Maho Ishikawa
Hitomi Nakayama
Eriko Sato
Takayuki Tabayashi
Toru Mitsumori
Tomoiku Takaku
Tomonori Nakazato
Michihide Tokuhira
Hiroyuki Fujita
Miki Ando
Yoshihiro Hatta
Tatsuya Kawaguchi
Publication date: 08-04-2024
Publisher: Springer Nature Singapore
Keywords: Imatinib
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Chronic Myeloid Leukemia
Nilotinib
Dasatinib
Published in: International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-024-03758-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer